0 4 alkyl as used in this application to describe substituents r 1 to r 5 includes pyrrolidinyl methyl where the methyl is the point of attachment to ring a for example u201c halogen u201d or halo preferably represents chloro or fluoro but may also be bromo or iodo u201c treat u201d u201c treating u201d and u201c treatment u201d refer to a method of alleviating or abating a disease and or its attendant symptoms the present invention provides compounds compositions and methods for the treatment of kinase related disease particularly iptkb related diseases for example autoimmune diseases particularly b cell associated diseases are related to iptkb for example rheumatoid arthritis systemic lupus erythematosus sle immune thrombocytopenic purpura itp and hemolytic anemia in one embodiment with reference to compounds of formula i n is selected from 1 and 2 m is selected from 0 1 and 2 and a can have up to 3 groups selected from u2014 cr 1 u2550 u2014 cr 2 u2550 u2014 cr 3 u2550 u2014 cr 4 u2550 and u2014 cr 5 u2550 replaced with n in another embodiment r 2 r 3 and r 4 are independently selected from hydrogen hydroxy halo cyano c 1 6 alkyl halo substituted c 1 6 alkyl hydroxy substituted c 1 6 alkyl cyano substituted c 1 6 alkyl c 3 8 heterocycloalkyl c 0 4 alkyl c 1 10 heteroaryl c 0 4 alkyl u2014 xso 2 r 11 u2014 xso 2 nr.